Next-generation sequencing's biologics safety testing commercial disruption — the application of metagenomic NGS technology to biopharmaceutical adventitious agent detection — enabling unbiased, comprehensive screening for any potential viral, bacterial, or mycoplasma contamination in biological drug products without the limitations of targeted PCR or culture methods that can only...